Associations between being a former or current smoker and the odds of having AAV were observed across subgroups of patients with selected AAV manifestations. have differences in genetic risk, pathogenesis, and response to treatment compared with those with proteinase 3 antibodies. Meaning The association between AAV and cigarette smoking identifies a modifiable risk factor for AAV and may suggest a possible pathogenic mechanism between respiratory exposures and development of AAV. This case-control study examines the association of cigarette smoking with the odds of having antineutrophil cytoplasmic antibodyCassociated vasculitis. Abstract Importance Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic small vessel vasculitis characterized by circulating ANCAs targeting proteinase 3 (PR3) or myeloperoxidase (MPO) Rabbit Polyclonal to SHD and associated with excess morbidity and mortality. Myeloperoxidase-ANCACpositive AAV and PR3-ANCACpositive AAV are increasingly recognized to have differences in genetic risk, pathogenesis, and response to treatment. Risk factors for AAV, including cigarette smoking, are poorly understood. Objective To examine the association between cigarette smoking and AAV. Design, Setting, and Participants This case-control study included a consecutive inception cohort of 484 patients with AAV diagnosed from 2002 to 2017 compared with a cohort of sex-, race-, and age-matched controls. Eleven cases were excluded owing to discordant smoking information in the electronic health record. Controls were randomly selected from participants recruited to the Partners HealthCare Biobank between its inception in 2010 MK-6913 2010 and 2018 and who completed a smoking questionnaire and were not diagnosed with AAV (n?=?30?536). Exposures Smoking status (current, former, never) and pack-years of cigarette smoking were determined from review of the electronic medical record and smoking questionnaires. Main Outcomes and Measures Patients with AAV were individually matched with 3 randomly-selected controls based on sex, race, and age (within 2 years difference). Conditional logistic regression was performed to examine the association between cigarette smoking and AAV using odds ratios (OR) and MK-6913 95% confidence intervals (CIs). Results Overall, 473 cases MK-6913 were matched with 1419 controls (mean [SD] age, 59 [16] years; 281 women [59%], 396 white [84%]). Patients with AAV were more likely to be former (OR, 1.6; 95% CI, 1.3-2.0) or current smokers (OR, 2.7; 95% CI, 1.8-4.1); there was a dose-response relationship according to pack-years of exposure (value of <.05 was used as the threshold for statistical significance and SAS statistical software (version 9.4; SAS Institute, Inc) was used for all statistical analyses. Results Baseline characteristics of participants with AAV and controls are included in Table 1. Of 484 participants with AAV, 1 did not have smoking status documented and 10 participants with AAV had discordant smoking statuses recorded in several notes and/or structured data fields and were excluded from the study. A total of 473 AAV cases were matched to 1419 controls from the Partners Biobank. Table 1. Characteristics of Patients With Antineutrophil Cytoplasmic AntibodyCAssociated Vasculitis (AAV) for trend <.001) (Figure). Patients with the greatest cumulative pack-year exposure (60 pack-years) to cigarette smoking had the greatest odds of having AAV (OR, 30.3; 95% CI, 8.7-105.6) compared with never smokers. Table 2. The Association of Cigarette Smoking With the Odds of Having Antineutrophil Cytoplasmic AntibodyCAssociated Vasculitis (AAV)a Variable No. (%) Odds Ratio (95% CI) AAV Control

Ever smoker Never219 (46)823 (58)1 [Reference] Ever smoker254 (54)596 (42)1.72 (1.37-2.15)Overall Never219 (46)823 (58)1 [Reference] MK-6913 Former211 (45)533 (38)1.58 (1.25-2.00) Current43 (9)63 (4)2.70 (1.76-4.14)Age <60, y Never129 (57)476 (70)1 [Reference] Former68 (30)158 (23)1.71 (1.18-2.47) Current31 (14)44 (6)2.80 (1.67-4.70)Age 60, y Never90 (37)347 (47)1 [Reference] Former143 (58)375 (51)1.51 (1.11-2.06) Current12 (5)19 (3)2.85 (1.29-6.30)Male Never81 (42)343 (60)1 [Reference] Former95 (49)212 (37)2.14 (1.46-3.13) Current16 (8)21 (4)3.62 (1.73-7.55)Female Never138 (49)480 (57)1 [Reference] Former116 (41)321 (38)1.29 (0.95-1.75) Current27 (10)42 (5)2.30 (1.35-3.90)PR3-ANCA positive Never86 (52)290 (59)1 [Reference] Former64 (39)173 (35)1.31 (0.87-1.99) Current14 (9)29 (6)1.71 MK-6913 (0.84-3.47)MPO-ANCA positive Never133 (43)533 (58)1 [Reference] Former147 (48)360 (39)1.73 (1.29-2.30) Current29 (9)34 (4)3.54 (2.05-6.10)Head and neck disease Never108 (50)392 (60)1 [Reference] Former91 (42)223 (34)1.58.